Glow cll study
WebOct 7, 2024 · PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). METHODS Previously untreated CLL patients age < 70 … WebDec 13, 2024 · “The GLOW study results demonstrate the potential of fixed-duration I+V to become an additional treatment option for older, unfit patients with CLL in the first-line setting, and this fixed-dose combination may offer a flexible regimen for patients seeking a time-limited treatment approach,” said study investigator Carsten Niemann,† M.D ...
Glow cll study
Did you know?
WebDec 12, 2024 · Slideset Download. Conference Coverage. Updated results from the phase III GLOW trial show that first-line, fixed-duration ibrutinib + venetoclax confers deep and prolonged undetectable MRD responses, leading to favorable PFS outcomes for older or unfit patients with CLL. Released: December 12, 2024. WebGLOW is the first randomized study of first-line FD I+V in CLL/small lymphocytic lymphoma (SLL). Aims. To evaluate efficacy and safety of FD I+V vs Clb+O in previously untreated CLL/SLL. Methods. GLOW (NCT03462719) enrolled patients (pts) aged ≥65 years or 18-64 years with cumulative illness rating scale (CIRS) score >6 or creatinine ...
WebDec 11, 2024 · This better in comparison to chlorambucil plus obinutuzumab (Gazyva) in elderly and unfit patients with chronic lymphocytic leukemia (CLL), according to findings from the phase 3 GLOW study (NCT03462719) that were presented at the 2024 ASH Annual Meeting and Exposition. 1 WebJun 10, 2024 · A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and …
WebDec 10, 2024 · “The GLOW study results demonstrate the potential of fixed-duration I+V as an additional treatment option for older, unfit patients with CLL in the first-line setting, …
WebJun 2, 2024 · CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). …
WebDec 1, 2024 · Purpose: CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following … do apple watches connect to wifiWebDec 10, 2024 · The Phase 3 GLOW study (n=211; median age, 71 years) is a randomised, open-label trial which evaluated the efficacy and safety of first-line, fixed-duration I+V vs. Clb+O in elderly patients (≥ ... do apple watches need new batteriesWebJun 24, 2024 · About the GLOW study. The Phase 3 GLOW study (N=211; median age, 71 years) is a randomised, open-label trial which evaluated the efficacy and safety of first-line, fixed-duration I+V vs. Clb+O in elderly patients (≥65 years of age) with CLL/SLL, or patients ages 18-64 with a cumulative illness rating scale (CIRS) score of greater than six or ... create your own banking systemWebChasing PFS. The Phase III GLOW study (NCT03462719) provided the first prospective data on MRD outcomes in patients treated with ibrutinib+ venetoclax versus Clb+O for … create your own bank checksWebSep 22, 2016 · Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms ... Diagnosis of CLL/SLL that meets 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) diagnostic criteria (Hallek et al), with active disease meeting at least 1 IWCLL criteria for requiring … create your own banner adsWebJul 13, 2024 · Ghia: GLOW is a phase 3 international study where treatment-naïve patients with CLL were randomized to [receive] either the combination of ibrutinib plus venetoclax, or standard-of-care treatment ... create your own banner party cityWebNov 4, 2024 · At ASH, AbbVie will present data from the Phase 2 CAPTIVATE and Phase 3 GLOW studies evaluating minimal residual disease and disease-free survival outcomes with fixed duration treatment in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) who received the ibrutinib (IMBRUVICA ®) + venetoclax … do appliances come with a home